Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology
Cancer Immunol Immunother 2021
Limited data are available on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with preexisting autoimmune diseases… Read More
Adverse Events Associated with Immune Checkpoint Blockade
N Engl J Med 2018
A case of PR3-ANCA GPA developing after checkpoint blockade is described. Read More
Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients
Sci Rep 2020
The ‘real-world’ patient population of metastatic melanoma is not fully represented in clinical trials investigating checkpoint inhibitors. We described therapy discontinuation… Read More
Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort
Autoimmun Rev 2020
Objective: Although immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, their use is associated with immune toxicities referred to as immune-related… Read More
Moving towards personalized treatments of immune-related adverse events
Nat Rev Clin Oncol 2020
The enhancement of immune responses upon treatment with immune checkpoint inhibitors can have the desired outcome of reinvigorating antitumour… Read More
Immune Checkpoint Inhibitors in Cancer Immunotherapy
Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy
N Engl J Med 2020
A case description of the successful use of tofacitinib in a patient with gastric cancer receiving pembrolizumab whose… Read More
Checking in with immune checkpoint inhibitors: Results of a needs assessment survey of Canadian rheumatologists
J Cancer Sci Therap 2019
Objectives: Immune checkpoint inhibitors (ICI) are associated with immune-related adverse events (irAE), including autoimmune rheumatologic diseases. The Canadian Research… Read More
Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist
J Rheum 2019
Immune checkpoint inhibitors have revolutionized cancer therapy by blocking inhibitory pathways of the immune system to fight cancer cells. Their use… Read More
Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis
Clin Rheumatol 2019
Immunotherapy for cancer treatment continues to evolve, and immune checkpoints have proven successful therapeutic targets. With success has come the challenge… Read More